SAN DIEGO, April 7, 2008 /PRNewswire-FirstCall/ -- Ardea
Biosciences, Inc. (NASDAQ:RDEA) today announced that data will be
presented on its second generation non-nucleoside reverse
transcriptase inhibitors (NNRTIs), at the 21st International
Conference on Antiviral Research (ICAR). Additionally, data on
two of the Company's mitogen-activated ERK kinase (MEK)
inhibitors, RDEA119 and RDEA436, will be presented at the
American Association for Cancer Research (AACR) annual meeting.
The presentation details are as follows:
-- 21st ICAR in Montreal, Quebec, Canada
Date/Time: Monday, April 14, 2008 at 4:00 p.m. Eastern Time
Title: A Novel NNRTI Class with Potent Anti-HIV Activity against
NNRTI-Resistant Viruses
Location: Poster Session 1 (Poster #80)
-- AACR Annual Meeting in San Diego, California
Date/Time: Tuesday, April 15, 2008 at 1:00 p.m. Pacific Time
Title: RDEA119, a Potent and Highly Specific MEK Inhibitor is
Efficacious in Mouse Tumor Xenograft Studies
Location: Poster Session 32 (Poster #4878), Exhibit Hall B-F
Date/Time: Tuesday, April 15, 2008 at 1:00 p.m. Pacific Time
Title: RDEA436, a Novel MEK Inhibitor with Favorable
Pharmacokinetic Properties
Location: Poster Session 32 (Poster #4895), Exhibit Hall B-F
About Ardea Biosciences, Inc.
Ardea Biosciences, of San Diego, California, is a biotechnology
company focused on the discovery and development of
small-molecule therapeutics for the treatment of HIV, cancer and
inflammatory diseases, including gout. We have three drug
candidates in clinical trials and several others in preclinical
development and discovery. Our most advanced drug candidate is
RDEA806, a non-nucleoside reverse transcriptase inhibitor
(NNRTI), which is in a Phase 2a study for the treatment of HIV.
We are also investigating RDEA806 for the treatment of gout. Our
lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, is in
a Phase 1 study in advanced cancer patients and is being
investigated for the treatment of inflammatory diseases.
RDEA436, our second generation MEK inhibitor for the treatment of
cancer and inflammatory diseases, has been evaluated in a human
micro-dose pharmacokinetic study and has been selected as a
development candidate. In addition to the foregoing clinical
programs, we are developing a second generation NNRTI for HIV, as
well as other drug candidates in earlier stages of preclinical
development and discovery.
Statements contained in this press release regarding matters that
are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding:
sufficiency of cash resources and our goals, including the
expected properties and benefits of RDEA806, RDEA119, RDEA436 and
our other compounds and the results of preclinical, clinical and
other studies. Risks that contribute to the uncertain nature of
the forward-looking statements include: risks related to the
outcome of preclinical and clinical studies, risks related to
regulatory approvals, delays in commencement of preclinical and
clinical studies, and costs associated with internal development
and in-licensing activities. These and other risks and
uncertainties are described more fully in our most recently filed
SEC documents, including our Annual Report on Form 10-K and our
Quarterly Reports on Form 10-Q, under the headings "Risk
Factors." All forward-looking statements contained in this press
release speak only as of the date on which they were made. We
undertake no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Source: Ardea Biosciences, Inc.
CONTACT: Edie DeVine of WeissComm Partners, +1-415-946-1081, for
Ardea Biosciences, Inc.